Markets:

Overview

News

Currencies

International

Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

16.39 +0.05 (+0.31%)

Streaming Delayed Price Updated: 12:07 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 27, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 26, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

February 20, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Insiders Buying Dorian LPG And 2 Other Stocks ↗

January 17, 2024

Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.

Via Benzinga

KalVista Pharma: Q2 Earnings Insights ↗

December 07, 2023

Via Benzinga

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 16, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 15, 2024

Via Benzinga

KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants

February 15, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 14, 2024

Via Benzinga

KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

February 14, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

February 14, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

What's Going With Hereditary Angioedema-Focused KalVista Pharmaceuticals Stock On Tuesday? ↗

February 13, 2024

Results from KalVista Pharmaceuticals' Phase 3 KONFIDENT trial. Sebetralstat, an oral on-demand therapy, shows efficacy for hereditary angioedema.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 13, 2024

Via Benzinga

KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

February 13, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Insiders Buying Monro And 3 Other Stocks ↗

February 09, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying ↗

February 02, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 02, 2024

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

January 30, 2024

Although U.S. stocks closed higher on Monday, there were a few notable insider trades.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

January 22, 2024

Via Benzinga

$230M Bet On Talos Energy? Check Out These 4 Stocks Insiders Are Buying ↗

January 22, 2024

Although U.S. stocks closed higher on Friday, there were a few notable insider trades.

Via Benzinga

Insiders Buying KalVista Pharmaceuticals And 3 Other Stocks ↗

January 11, 2024

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

Via Benzinga

$6.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

January 08, 2024

Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades.

Via Benzinga

Around $2.4M Bet On HighPeak Energy? Check Out These 4 Stocks Insiders Are Buying ↗

January 02, 2024

Although U.S. stocks closed lower on Friday, there were a few notable insider trades.

Via Benzinga

KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology

December 20, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024 ↗

December 07, 2023

KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

December 07, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

3 Micro-Cap Stocks That Could Be Moonshots ↗

November 14, 2023

If you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields.

Via InvestorPlace

KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

November 14, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved

November 13, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.